Newly identified events in the RE-LY trial.
Stuart J
SJ
Connolly
Michael D
MD
Ezekowitz
Salim
S
Yusuf
Paul A
PA
Reilly
Lars
L
Wallentin
D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D000069604:Dabigatran; D004617:Embolism / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology; D011725:Pyridines / Q000009:adverse effects*
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran